INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,397,000 | +8.2% | 17,435,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $10,534,000 | 0.0% | 17,435,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $10,534,000 | -3.8% | 17,435,000 | -4.7% | 0.00% | 0.0% |
| Q3 2021 | $10,953,000 | -9.7% | 18,294,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $12,131,000 | +2.3% | 18,294,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $11,858,000 | +7.0% | 18,294,000 | -1.8% | 0.00% | 0.0% |
| Q4 2020 | $11,087,000 | +24.0% | 18,622,000 | +43.2% | 0.00% | 0.0% |
| Q3 2020 | $8,940,000 | -4.2% | 13,005,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $9,330,000 | +87.8% | 13,005,000 | +122.8% | 0.00% | 0.0% |
| Q1 2020 | $4,967,000 | -27.9% | 5,838,000 | +12.1% | 0.00% | 0.0% |
| Q4 2019 | $6,892,000 | +47.2% | 5,209,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $4,682,000 | -6.3% | 5,209,000 | +3.2% | 0.00% | 0.0% |
| Q2 2019 | $4,995,000 | – | 5,048,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $13,303 | 4.18% |
| Context Capital Management, LLC | 20,230 | $16,727 | 1.40% |
| OAKTREE CAPITAL MANAGEMENT LP | 8,816,000 | $7,289,292 | 0.08% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $187,043 | 0.04% |
| Calamos Advisors LLC | 5,000,000 | $4,156,550 | 0.02% |
| FRANKLIN RESOURCES INC | 21,000,000 | $17,363,331 | 0.01% |
| Russell Investments Group, Ltd. | 1,785,000 | $1,497,379 | 0.00% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,000,000 | $2,481,591 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |